| Clinical data | |
|---|---|
| Other names | 1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.164.683 |
| Chemical and physical data | |
| Formula | C14H16ClN3O |
| Molar mass | 277.75 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
JNJ-7777120 was a drug being developed byJohnson & Johnson Pharmaceutical Research & Development which acts as a potent and selectiveantagonist at thehistamine H4 receptor.[1] It hasanti-inflammatory effects,[2] and has been demonstrated to be superior to traditional (H1) antihistamines in the treatment ofpruritus (itching).[3] The drug was abandoned because of its shortin vivohalf-life andhypoadrenocorticism toxicity in rats and dogs, that prevented advancing it into clinical studies.[4]
Thispharmacology-related article is astub. You can help Wikipedia byexpanding it. |